Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 16 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

Potential adjunct disease-modifying effects of exercise and physical activity in multiple sclerosis: an umbrella review of disease activity/progression, safety, and inflammatory-neurobiomarker evidence

Abstract

BackgroundMultiple sclerosis (MS) is characterized by inflammatory activity and neurodegeneration; disease-modifying therapies incompletely address progression. Exercise is established for symptomatic benefit and has been proposed as an adjunct disease-modifying strategy, but review-level evidence is fragmented. Objective: To synthesize and appraise systematic-review evidence on structured exercise or physical activity for disease activity/progression, safety, and inflammatory/immune and neurobiomarker outcomes in adults with MS.MethodsThis umbrella review followed PRISMA 2020 and PRIOR; PubMed, Web of Science Core Collection, Embase, Cochrane Database of Systematic Reviews, Scopus, and SPORTDiscus were searched from inception to 8 October 2026. Eligible units were systematic reviews, meta-analyses, network meta-analyses, and dose-response meta-analyses. Two reviewers independently selected reviews, extracted data, and assessed methodological quality (AMSTAR 2), primary-study overlap (corrected covered area, CCA), and certainty (GRADE or CINeMA). Estimates were classified by estimand, and only comparisons of exercise with non-exercise comparators informed conclusions about intervention effects. Because biomarker clusters had high or very high overlap and source estimates were heterogeneous, no umbrella-level pooling was performed.ResultsTwenty-two reviews (2014–2026) were included. In trials reporting safety outcomes, no increased risk of relapse (RR 0.95, 95% CI 0.61–1.48) or serious adverse events (RR 1.05, 95% CI 0.62–1.80) was detected, although both intervals were wide, and any adverse event was more frequent but imprecise (RR 1.40, 95% CI 0.90–2.19). Against non-exercise controls, BDNF was higher after chronic training (SMD 0.78, 95% CI 0.27–1.28), and one meta-analysis reported lower TNF-α, interferon-γ, and interleukin-17. NfL decreased within exercise arms (SMD −0.55; not an intervention effect), and controlled trials were inconsistent (one small trial favorable, two larger trials null). No effect on relapse, EDSS (SMD 0.02, 95% CI −0.40 to 0.44), or MRI outcomes was shown; MSFC improved in three small trials (very low certainty). All reviews had low or critically low AMSTAR 2 confidence, and certainty was low for two outcomes and very low for 19.ConclusionCurrent review-level evidence does not indicate an increased risk of relapse or serious adverse events associated with exercise in adults with MS. Exercise may modulate selected biomarkers, but the available evidence does not demonstrate a disease-modifying effect.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261410063.

Related

  1. Healing helminths: A systematic review of the anti-inflammatory and disease-modifying potential of helminth-derived proteins
    Sienna Stucke, Aonghus Feeney, Richard Lalor +4
    Molecular TherapyPeer-reviewedCC BY 4.0Full text1 citedMicrobiologyPMC
  2. Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.
    Zubeyir Salis, Simona Truglia, Oliver Distler +11
    Arthritis Care and ResearchPeer-reviewedCC BYFull textGeneral biologyHAL
  3. Environmental and lifestyle factors in multiple sclerosis progression
    Anna Karin Hedström
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossrefPMCEurope PMC
  4. Disease progression shapes circadian and locomotor disruption in a model of multiple sclerosis
    V. W. Li, J. P. Segal, N. Ghasemlou
    bioRxivPreprintCC BYFull textZoology & animal behaviourbioRxiv
  5. Prognostic role of nailfold videocapillaroscopy in predicting progression in systemic sclerosis-associated interstitial lung disease: a systematic review and narrative synthesis
    Milan Bogojevic, Rifat Medjedovic, Milica Markovic +3
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
BibTeX
@article{dai2026potential,
  title = {{Potential adjunct disease-modifying effects of exercise and physical activity in multiple sclerosis: an umbrella review of disease activity/progression, safety, and inflammatory-neurobiomarker evidence}},
  author = {Jianmin Dai and Weibao Liang and Yufeng Kang and Mohan Sun and Jingwei Fang and Yue Zong and Leigang Song},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = nov,
  doi = {10.3389/fimmu.2026.1933579},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1933579},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Potential adjunct disease-modifying effects of exercise and physical activity in multiple sclerosis: an umbrella review of disease activity/progression, safety, and inflammatory-neurobiomarker evidence
AU  - Jianmin Dai
AU  - Weibao Liang
AU  - Yufeng Kang
AU  - Mohan Sun
AU  - Jingwei Fang
AU  - Yue Zong
AU  - Leigang Song
PY  - 2026
DA  - 2026/11/16
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1933579
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1933579
AB  - BackgroundMultiple sclerosis (MS) is characterized by inflammatory activity and neurodegeneration; disease-modifying therapies incompletely address progression. Exercise is established for symptomatic benefit and has been proposed as an adjunct disease-modifying strategy, but review-level evidence is fragmented. Objective: To synthesize and appraise systematic-review evidence on structured exercise or physical activity for disease activity/progression, safety, and inflammatory/immune and neurobiomarker outcomes in adults with MS.MethodsThis umbrella review followed PRISMA 2020 and PRIOR; PubMed, Web of Science Core Collection, Embase, Cochrane Database of Systematic Reviews, Scopus, and SPORTDiscus were searched from inception to 8 October 2026. Eligible units were systematic reviews, meta-analyses, network meta-analyses, and dose-response meta-analyses. Two reviewers independently selected reviews, extracted data, and assessed methodological quality (AMSTAR 2), primary-study overlap (corrected covered area, CCA), and certainty (GRADE or CINeMA). Estimates were classified by estimand, and only comparisons of exercise with non-exercise comparators informed conclusions about intervention effects. Because biomarker clusters had high or very high overlap and source estimates were heterogeneous, no umbrella-level pooling was performed.ResultsTwenty-two reviews (2014–2026) were included. In trials reporting safety outcomes, no increased risk of relapse (RR 0.95, 95% CI 0.61–1.48) or serious adverse events (RR 1.05, 95% CI 0.62–1.80) was detected, although both intervals were wide, and any adverse event was more frequent but imprecise (RR 1.40, 95% CI 0.90–2.19). Against non-exercise controls, BDNF was higher after chronic training (SMD 0.78, 95% CI 0.27–1.28), and one meta-analysis reported lower TNF-α, interferon-γ, and interleukin-17. NfL decreased within exercise arms (SMD −0.55; not an intervention effect), and controlled trials were inconsistent (one small trial favorable, two larger trials null). No effect on relapse, EDSS (SMD 0.02, 95% CI −0.40 to 0.44), or MRI outcomes was shown; MSFC improved in three small trials (very low certainty). All reviews had low or critically low AMSTAR 2 confidence, and certainty was low for two outcomes and very low for 19.ConclusionCurrent review-level evidence does not indicate an increased risk of relapse or serious adverse events associated with exercise in adults with MS. Exercise may modulate selected biomarkers, but the available evidence does not demonstrate a disease-modifying effect.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261410063.
SN  - 1664-3224
ER  -